APO Research
Talk to an analyst

APO RESEARCH · REPORT

Candidiasis Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Candidiasis Drug Market Outlook and Growth Opportunities 2026

2 January 2026191 pages

Choose your research edition.

Industry ResearchCandidiasis Drug Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Candidiasis Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Candidiasis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Candidiasis Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Candidiasis Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Candidiasis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Candidiasis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Candidiasis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Candidiasis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Candidiasis Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Candidiasis Drug market include Bristol-Myers Squibb, Cisen Pharmaceutical, Effik, Kingyork Group, Perrigo, Bayer, Pfizer, J & J and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Candidiasis Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Candidiasis Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Candidiasis Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Candidiasis Drug market.

Candidiasis Drug Segment by Company

Bristol-Myers Squibb

Cisen Pharmaceutical

Effik

Kingyork Group

Perrigo

Bayer

Pfizer

J & J

Sanofi

Teva

Candidiasis Drug Segment by Type

Oral

External Use

Other

Candidiasis Drug Segment by Application

Hospital

Retail Pharmacy

Other

Candidiasis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Candidiasis Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Candidiasis Drug key companies, revenue, market share, and recent developments.

3. To split the Candidiasis Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Candidiasis Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Candidiasis Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Candidiasis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Candidiasis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Candidiasis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Candidiasis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Candidiasis Drug industry.

Chapter 3: Detailed analysis of Candidiasis Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Candidiasis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Candidiasis Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Candidiasis Drug Industry Trends Table 2. Candidiasis Drug Industry Drivers Table 3. Candidiasis Drug Industry Opportunities and Challenges Table 4. Candidiasis Drug Industry Restraints Table 5. Global Candidiasis Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Candidiasis Drug Revenue Share by Company (2021-2026) Table 7. Global Candidiasis Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Candidiasis Drug Key Company Manufacturing Base & Headquarters Table 9. Global Candidiasis Drug Company, Product Type & Application Table 10. Global Candidiasis Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Candidiasis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oral Table 15. Significant Companies of External Use Table 16. Significant Companies of Other Table 17. Global Candidiasis Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Candidiasis Drug Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Candidiasis Drug Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Candidiasis Drug Sales Value Share by Type (2021-2026) Table 21. Global Candidiasis Drug Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Retail Pharmacy Table 24. Significant Companies of Other Table 25. Global Candidiasis Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Candidiasis Drug Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Candidiasis Drug Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Candidiasis Drug Sales Value Share by Application (2021-2026) Table 29. Global Candidiasis Drug Sales Value Share by Application (2027-2032) Table 30. Global Candidiasis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Candidiasis Drug Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Candidiasis Drug Sales Value Share by Region (2021-2026) Table 33. Global Candidiasis Drug Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Candidiasis Drug Sales Value Share by Region (2027-2032) Table 35. Global Candidiasis Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Candidiasis Drug Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Candidiasis Drug Sales Value Market Share by Country (2021-2026) Table 38. Global Candidiasis Drug Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Candidiasis Drug Sales Value Market Share by Country (2027-2032) Table 40. Bristol-Myers Squibb Company Information Table 41. Bristol-Myers Squibb Business Overview Table 42. Bristol-Myers Squibb Candidiasis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Bristol-Myers Squibb Candidiasis Drug Product Portfolio Table 44. Bristol-Myers Squibb Recent Development Table 45. Cisen Pharmaceutical Company Information Table 46. Cisen Pharmaceutical Business Overview Table 47. Cisen Pharmaceutical Candidiasis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Cisen Pharmaceutical Candidiasis Drug Product Portfolio Table 49. Cisen Pharmaceutical Recent Development Table 50. Effik Company Information Table 51. Effik Business Overview Table 52. Effik Candidiasis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Effik Candidiasis Drug Product Portfolio Table 54. Effik Recent Development Table 55. Kingyork Group Company Information Table 56. Kingyork Group Business Overview Table 57. Kingyork Group Candidiasis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Kingyork Group Candidiasis Drug Product Portfolio Table 59. Kingyork Group Recent Development Table 60. Perrigo Company Information Table 61. Perrigo Business Overview Table 62. Perrigo Candidiasis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Perrigo Candidiasis Drug Product Portfolio Table 64. Perrigo Recent Development Table 65. Bayer Company Information Table 66. Bayer Business Overview Table 67. Bayer Candidiasis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Bayer Candidiasis Drug Product Portfolio Table 69. Bayer Recent Development Table 70. Pfizer Company Information Table 71. Pfizer Business Overview Table 72. Pfizer Candidiasis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Pfizer Candidiasis Drug Product Portfolio Table 74. Pfizer Recent Development Table 75. J & J Company Information Table 76. J & J Business Overview Table 77. J & J Candidiasis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. J & J Candidiasis Drug Product Portfolio Table 79. J & J Recent Development Table 80. Sanofi Company Information Table 81. Sanofi Business Overview Table 82. Sanofi Candidiasis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Sanofi Candidiasis Drug Product Portfolio Table 84. Sanofi Recent Development Table 85. Teva Company Information Table 86. Teva Business Overview Table 87. Teva Candidiasis Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Teva Candidiasis Drug Product Portfolio Table 89. Teva Recent Development Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Candidiasis Drug Product Image Figure 2. Global Candidiasis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Candidiasis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Candidiasis Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oral Image Figure 8. External Use Image Figure 9. Other Image Figure 10. Global Candidiasis Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Candidiasis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Candidiasis Drug Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Retail Pharmacy Image Figure 15. Other Image Figure 16. Global Candidiasis Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Candidiasis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Candidiasis Drug Sales Value Share by Application (2021-2032) Figure 19. Global Candidiasis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Candidiasis Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Candidiasis Drug Sales Value (2021-2032) & (US$ Million) Figure 22. North America Candidiasis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Candidiasis Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Candidiasis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Candidiasis Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Candidiasis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Candidiasis Drug Sales Value (2021-2032) & (US$ Million) Figure 28. South America Candidiasis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Candidiasis Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Candidiasis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Candidiasis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Candidiasis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Candidiasis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • External Use
  • Other
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Bristol-Myers Squibb
  • Cisen Pharmaceutical
  • Effik
  • Kingyork Group
  • Perrigo
  • Bayer
  • Pfizer
  • J & J
  • Sanofi
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Candidiasis Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Candidiasis Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Candidiasis Drug Market Dynamics
  1. 2.1 Candidiasis Drug Industry Trends
  2. 2.2 Candidiasis Drug Industry Drivers
  3. 2.3 Candidiasis Drug Industry Opportunities and Challenges
  4. 2.4 Candidiasis Drug Industry Restraints
3 Candidiasis Drug Market by Company
  1. 3.1 Global Candidiasis Drug Company Revenue Ranking in 2025
  2. 3.2 Global Candidiasis Drug Revenue by Company (2021-2026)
  3. 3.3 Global Candidiasis Drug Company Ranking (2024-2026)
  4. 3.4 Global Candidiasis Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Candidiasis Drug Company Product Type and Application
  6. 3.6 Global Candidiasis Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Candidiasis Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Candidiasis Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Candidiasis Drug Market by Type
  1. 4.1 Candidiasis Drug Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 External Use
  4. 4.1.3 Other
  5. 4.2 Global Candidiasis Drug Sales Value by Type
  6. 4.2.1 Global Candidiasis Drug Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Candidiasis Drug Sales Value by Type (2021-2032)
  8. 4.2.3 Global Candidiasis Drug Sales Value Share by Type (2021-2032)
5 Candidiasis Drug Market by Application
  1. 5.1 Candidiasis Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Candidiasis Drug Sales Value by Application
  6. 5.2.1 Global Candidiasis Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Candidiasis Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Candidiasis Drug Sales Value Share by Application (2021-2032)
6 Candidiasis Drug Regional Value Analysis
  1. 6.1 Global Candidiasis Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Candidiasis Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Candidiasis Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Candidiasis Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Candidiasis Drug Sales Value (2021-2032)
  7. 6.3.2 North America Candidiasis Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Candidiasis Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Candidiasis Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Candidiasis Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Candidiasis Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Candidiasis Drug Sales Value (2021-2032)
  16. 6.6.2 South America Candidiasis Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Candidiasis Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Candidiasis Drug Sales Value Share by Country, 2025 VS 2032
7 Candidiasis Drug Country-level Value Analysis
  1. 7.1 Global Candidiasis Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Candidiasis Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Candidiasis Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Candidiasis Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Candidiasis Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Candidiasis Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Candidiasis Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Candidiasis Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Candidiasis Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Candidiasis Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Candidiasis Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Candidiasis Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Candidiasis Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Candidiasis Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Candidiasis Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Candidiasis Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Candidiasis Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Candidiasis Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Candidiasis Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Candidiasis Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Candidiasis Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Candidiasis Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Candidiasis Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Candidiasis Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Candidiasis Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Candidiasis Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Candidiasis Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Candidiasis Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Candidiasis Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Candidiasis Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Candidiasis Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Candidiasis Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Candidiasis Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Candidiasis Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol-Myers Squibb
  2. 8.1.1 Bristol-Myers Squibb Company Information
  3. 8.1.2 Bristol-Myers Squibb Business Overview
  4. 8.1.3 Bristol-Myers Squibb Candidiasis Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bristol-Myers Squibb Candidiasis Drug Product Portfolio
  6. 8.1.5 Bristol-Myers Squibb Recent Developments
  7. 8.2 Cisen Pharmaceutical
  8. 8.2.1 Cisen Pharmaceutical Company Information
  9. 8.2.2 Cisen Pharmaceutical Business Overview
  10. 8.2.3 Cisen Pharmaceutical Candidiasis Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Cisen Pharmaceutical Candidiasis Drug Product Portfolio
  12. 8.2.5 Cisen Pharmaceutical Recent Developments
  13. 8.3 Effik
  14. 8.3.1 Effik Company Information
  15. 8.3.2 Effik Business Overview
  16. 8.3.3 Effik Candidiasis Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Effik Candidiasis Drug Product Portfolio
  18. 8.3.5 Effik Recent Developments
  19. 8.4 Kingyork Group
  20. 8.4.1 Kingyork Group Company Information
  21. 8.4.2 Kingyork Group Business Overview
  22. 8.4.3 Kingyork Group Candidiasis Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Kingyork Group Candidiasis Drug Product Portfolio
  24. 8.4.5 Kingyork Group Recent Developments
  25. 8.5 Perrigo
  26. 8.5.1 Perrigo Company Information
  27. 8.5.2 Perrigo Business Overview
  28. 8.5.3 Perrigo Candidiasis Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Perrigo Candidiasis Drug Product Portfolio
  30. 8.5.5 Perrigo Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Candidiasis Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Candidiasis Drug Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Candidiasis Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Candidiasis Drug Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 J & J
  44. 8.8.1 J & J Company Information
  45. 8.8.2 J & J Business Overview
  46. 8.8.3 J & J Candidiasis Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 J & J Candidiasis Drug Product Portfolio
  48. 8.8.5 J & J Recent Developments
  49. 8.9 Sanofi
  50. 8.9.1 Sanofi Company Information
  51. 8.9.2 Sanofi Business Overview
  52. 8.9.3 Sanofi Candidiasis Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sanofi Candidiasis Drug Product Portfolio
  54. 8.9.5 Sanofi Recent Developments
  55. 8.10 Teva
  56. 8.10.1 Teva Company Information
  57. 8.10.2 Teva Business Overview
  58. 8.10.3 Teva Candidiasis Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Teva Candidiasis Drug Product Portfolio
  60. 8.10.5 Teva Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst